Caricamento...
P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)
Immunotherapy trials for glioblastoma (GBM) have some effects but the efficacy was limited, some because of the low immunogenicity and diverse antigens for GBMs. Personalized selection of suitable peptides for patients is one way to conquer this problem. We conducted serial series of clinical trials...
Salvato in:
| Pubblicato in: | Neuro Oncol |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464231/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.187 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|